Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) EBIT (2024 - 2026)

Carlsmed filings provide 2 years of EBIT readings, the most recent being -$9.3 million for Q4 2025.

  • On a quarterly basis, EBIT fell 98.38% to -$9.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.6 million, a N/A change, with the full-year FY2025 number at -$30.6 million, down 26.75% from a year prior.
  • EBIT hit -$9.3 million in Q4 2025 for Carlsmed, down from -$9.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$4.7 million in Q4 2024 to a low of -$9.3 million in Q4 2025.